An unexpected actor intervened. A small nonprofit, the Meridian Collective, asked to run a controlled study. Their stated aim was to help people with neuro-degenerative trauma recover continuity by combining Combalma outputs with human-led therapy. They recruited participants, put consent forms under microscopes, and promised transparency. Aria watched their trials like a wary guardian. In Meridian’s controlled sessions, therapists used Combalma’s drafts as prompts—starting points for human narration rather than final truths. Results were messy but promising: participants who used the algorithm as a scaffold reported higher wellbeing metrics than those who only preserved fragments.